Efficacy and safety of the six-dose regimen of artemether-lumefantrine in pediatrics with uncomplicated Plasmodium falciparum malaria:: A pooled analysis of individual patient data

被引:64
作者
Makanga, Michael
Premjl, Zul
Falade, Catherine
Karbwang, Juntra
Mueller, Edgar A.
Andriano, Kim
Hunt, Philip
Ibarra de Palacios, Patricia
机构
[1] Tech Univ Dresden, Inst Clin Pharmacol, Publ Hlth Res Assoc Saxony, Fac Med, D-01307 Dresden, Germany
[2] Muhumbili Univ, Coll Hlth Sci, Dar Es Salaam, Tanzania
[3] EDCTP, Tygerberg, South Africa
[4] Kenya Govt Med Res Ctr, Kilifi, Kenya
[5] Univ Ibadan, Coll Med, Dept Pharmacol & Therapeut, Ibadan, Nigeria
[6] WHO, Special Programme Res & Training Trop Dis, CH-1211 Geneva, Switzerland
[7] Novartis Pharmaceut, E Hanover, NJ USA
[8] Novartis Horsham Res Ctr, Horsham, W Sussex, England
[9] Novartis Pharma AG, Basel, Switzerland
关键词
D O I
10.4269/ajtmh.2006.74.991
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Patient data from eight clinical trials were pooled and analyzed to study the efficacy and safety of the six-dose versus four-dose regimen of artemether-lumefantrine (coartemether; Coartem) in children weighing 5-25 kg. A total of 544 patients with uncomplicated P. falciparum malaria (six-dose: 343; four-dose: 201). matched for demographic and baseline characteristics and individual coartemether doses were included in the analysis. Analysis of day 28 cure rate based on the intention-to-treat and evaluable populations yielded corrected cure rates for the six-dose regimen of 93% and 96% compared with 61% and 76%, respectively, for the four-dose regimen (P < 0.0001 for both comparisons). Similarly high cure rates were achieved with the six-dose regimen in non-immune infants weighing as little as 5 kg. The six- and four-dose regimens were equally well tolerated. The main finding of this analysis is that the six-dose regimen of coartemether is safe and more efficacious than the four-dose regimen in children.
引用
收藏
页码:991 / 998
页数:8
相关论文
共 27 条
[21]   Randomized comparison of artemether-benflumetol and artesunate-mefloquine in treatment of multidrug-resistant falciparum malaria [J].
van Vugt, M ;
Brockman, A ;
Gemperli, B ;
Luxemburger, C ;
Gathmann, I ;
Royce, C ;
Slight, T ;
Looareesuwan, S ;
White, NJ ;
Nosten, F .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (01) :135-139
[22]   Efficacy of six doses of artemether-lumefantrine (benflumetol) in multidrug-resistant Plasmodium falciparum malaria [J].
van Vugt, M ;
Wilairatana, P ;
Gemperli, B ;
Gathmann, I ;
Phaipun, L ;
Brockman, A ;
Luxemburger, C ;
White, NJ ;
Nosten, F ;
Looareesuwan, S .
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 1999, 60 (06) :936-942
[23]  
Von Seidlein L, 1998, AM J TROP MED HYG, V58, P638
[24]   Prolongation of the QTc interval in African children treated for falciparum malaria [J].
VonSeidlein, L ;
Jaffar, S ;
Greenwood, B .
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 1997, 56 (05) :494-497
[25]   Treatment of African children with uncomplicated falciparum malaria with a new antimalarial drug, CGP 56697 [J].
vonSeidlein, L ;
Jaffar, S ;
Pinder, M ;
Haywood, M ;
Snounou, G ;
Gemperli, B ;
Gathmann, I ;
Royce, C ;
Greenwood, B .
JOURNAL OF INFECTIOUS DISEASES, 1997, 176 (04) :1113-1116
[26]   Antimalarial drug resistance [J].
White, NJ .
JOURNAL OF CLINICAL INVESTIGATION, 2004, 113 (08) :1084-1092
[27]  
*WHO, 2004, POS WHOS ROLL BACK M